
## **Carolina Feres**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2044070/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia. Current Treatment Options in Oncology, 2021, 22, 66.	3.0	13
2	Baseline total metabolic tumor volume (TMTV) application in Hodgkin lymphoma: a review article. Clinical and Translational Imaging, 2022, 10, 273-284.	2.1	4
3	Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib. Hematology, Transfusion and Cell Therapy, 2020, , .	0.2	2
4	Urinary retention after use of decitabine in acute myeloid leukemia: case report. Hematology, Transfusion and Cell Therapy, 2021, , .	0.2	1
5	Central Nervous System (CNS) Infiltration Assessment Using Cerebrospinal Fluid Flow Cytometry in Hematologic Malignancies: A Single Center Retrospective Analysis of Clinical Outcomes. Blood, 2019, 134, 5773-5773.	1.4	1
6	PET-CT Quantitative Parameter Delta Suvmax As a Predictor of Early Relapse in Patients with Difuse Large B-Cell Lymphoma. Blood, 2021, 138, 4580-4580.	1.4	1
7	Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell. Blood, 2021, 138, 2520-2520.	1.4	0
8	Proposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL). Blood, 2020, 136, 25-27.	1.4	0
9	COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study. Blood, 2020, 136, 35-36.	1.4	0
10	Cell of Origin Impacts Δsuvmax Cutoff for Prediction of Relapse in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 23-24.	1.4	0
11	Implementation of a Public Lymphoma Clinic in a Private Hospital in Brazil: Challenges and Impact of	1.4	0